BioSpace News Archive

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from two studies from the company’s leading lung cancer clinical development program evaluating KEYTRUDA,

A new online data collection tool has revealed shortages of crucial supplies, including commercial test kits needed for COVID-19 and other routine laboratory diagnostics.

New scientific review article finds promising results when comparing fall rates in patients with and without surgery

Since the beginning of this unprecedented-worldwide-health-crisis, Carenity, a digital health start-up specialized in medical studies whose platform brings together nearly 400,000 patients worldwide, has decided to give a voice to its chronic patients’ communities, a population that is particularly vulnerable in this context.

Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it has received a notice, and acknowledges the filing of, a preliminary consent solicitation statement by WaterMill Asset Management Corp., Mr. Robert W. Postma and affiliated parties who together report to own 7,173,650 shares of Ziopharm, stating they intend to solicit the written consent of stockholders to remove without cause four members of the Company’s B

Jaguar Health, Inc. announced that effective October 13, 2020, the Company has granted nonstatutory stock options for the purchase of up to 45,000 shares of the Company’s common stock to one new employee as inducement awards under the Company’s Inducement Award Plan.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of Venclexta®

Rx3000® UV-C Light, HEPA filtration combination inactivates and traps 99.9% of airborne viruses, bacteria, mold, fungi and particulates

Data From CENTAUR Trial Published in Muscle & Nerve Demonstrates That Administration of AMX0035 Results in Longer Survival for People With ALS Early Administration of AMX0035 Reduced the Risk of Death by 44% Over the Duration of Follow-Up AMX0035 is the First ALS Therapeutic to Demonstrate Both a Statistically Significant Survival and Functional Benefit in ALS in a Randomized Controlled Trial

Cellectis S.A. announced that its majority-owned subsidiary Calyxt, Inc., a plant-based technology company, has entered into definitive agreements with institutional investors for the purchase and sale of 3,750,000 shares of Calyxt’s common stock, at a purchase price of $4.00 per share, in a registered direct offering.